title: Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.
authors.affiliation: Departments of Hematology/Oncology, Mayo Clinic, Phoenix.
authors.forename: R K
authors.initials: RK
authors.lastname: Ramanathan
authors.affiliation: Core Lab, Imaging Endpoints, Scottsdale.
authors.forename: R L
authors.initials: RL
authors.lastname: Korn
authors.affiliation: Division of Medical Oncology, University of Washington, Seattle, WA.
authors.forename: E G
authors.initials: EG
authors.lastname: Chiorean
authors.affiliation: Department of Biostatistics, Celgene Corporation, Summit, NJ.
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.affiliation: Translational Drug Development, Translational Genomics Research Institute and Honor Health, Phoenix, USA dvh@tgen.org.
authors.forename: D D
authors.initials: DD
authors.lastname: Von Hoff
mesh_terms: D018395:CA-19-9 Antigen; D019788:Fluorodeoxyglucose F18; D006801:Humans; D010190:Pancreatic Neoplasms; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D018395:CA-19-9 Antigen; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18